Infertility

Lore & Background

Infertility is defined differently across organizations. The World Health Organization defines it as a disease of the reproductive system characterized by failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse, excluding breastfeeding or postpartum amenorrhea. Primary infertility refers to couples who have never had a child; secondary infertility is failure to conceive following a previous pregnancy. In the United States, a woman under 35 is considered infertile after 12 months of contraceptive-free intercourse, while a woman over 35 is considered infertile after six months. The UK's NICE guidelines recommend clinical assessment after one year for women of reproductive age, with earlier referral for women over 36.

Reader's Guide

Infertility is a significant medical and demographic concern, with prevalence estimates varying due to differing definitions. The most common causes of female infertility are hormonal, including low estrogen, PCOS, and aging, which reduce ovarian reserve. Tubal infertility accounts for 11–67% of female infertility, and endometriosis for 25–40%. Male infertility is most often due to semen deficiencies. About 85% of infertile couples have an identifiable cause, while 15% are unexplained. The condition is not applied to children before puberty or women after menopause, as these are natural states. Fertility awareness methods track cervical mucus, basal body temperature, or hormone measurements to identify the fertile window, which can last up to 7 days before and during ovulation.

Did You Know?

• Female fertility normally peaks in young adulthood and diminishes after age 35, with pregnancy occurring rarely after age 50.
• Male infertility is responsible for 20–30% of infertility cases, while 20–35% are due to female infertility.

Diagnosis and Identification

PMOS is the most common hormonal disorder affecting women of reproductive age, with prevalence estimates ranging from 5% to 18% across populations. The exact root cause remains uncertain, though a clear genetic component exists alongside environmental contributions. Diagnosis requires the presence of at least two of three clinical markers: irregular menstrual cycles, elevated testosterone or its visible manifestations such as excess facial hair, or an abundance of small antral follicles detectable on ultrasound. Notably, despite the older name "polycystic ovary syndrome," women with PMOS are not actually more likely to develop true ovarian cysts than those without the condition. A blood test measuring anti-Müllerian hormone levels can substitute for the ultrasound in diagnostic workups. Additional symptoms that may prompt investigation include heavy periods, persistent acne, difficulty conceiving, and patches of darker, velvety skin known as acanthosis nigricans.

The Symptom Landscape

PMOS presents a remarkably broad spectrum of signs, often emerging at puberty but sometimes concealed if oral contraceptives are initiated early. Menstrual irregularity sits at the center—periods may become infrequent, cease entirely, or arrive as unusually heavy flows. Around 40% of women with PMOS who maintain a regular cycle still experience ovulation-free bleeding. Hirsutism, a pattern of hair growth on the chin, upper lip, chest, upper thighs, and abdomen, affects approximately 60% of those with the condition. Severe acne that outlasts adolescence, androgenic hair loss at the crown of the scalp, persistently oily skin, and dark velvety patches are additional hallmarks. Testosterone levels tend to run about 1.5 times higher than in women without PMOS, and ovaries may appear enlarged with numerous small fluid-filled follicles surrounding eggs. The condition is also one of the leading causes of infertility in women, making reproductive challenges a defining concern for many affected individuals.

Metabolic and Long-Term Health Burden

The metabolic consequences of PMOS extend far beyond reproductive difficulties. Women with the condition face a three- to seven-fold elevated likelihood of developing metabolic disorders compared to those without. Insulin resistance is prevalent even among lean individuals, and when compounded by obesity, it significantly raises the risk of type 2 diabetes and metabolic dysfunction–associated steatotic liver disease, particularly when androgen levels are high. Between 30% and 80% of women with PMOS across different cultures and ancestries are overweight or obese, with marked weight gain occurring between adolescence and adulthood. Cardiovascular risk is also heightened: the incidence of stroke and coronary heart disease is roughly doubled compared to women of similar body mass without PMOS. Metabolic syndrome affects about 40% of those living with the condition. Perhaps most alarmingly, the risk of endometrial cancer is approximately three times higher, linked to infrequent periods and lower levels of sex hormone-binding globulin and progesterone. Sleep apnea is also more common, particularly when obesity is present.

Management and Fertility Pathways

Treatment for PMOS centers on alleviating day-to-day symptoms while mitigating long-term health risks. A healthy lifestyle and weight management form the foundation of general care. Hormonal contraception can regularize menstrual cycles and reduce both acne and unwanted hair growth, while metformin, a standard antidiabetic medication, helps improve insulin sensitivity. For women seeking to conceive, letrozole and other ovulation-induction methods offer a pathway to fertility, addressing PMOS's status as a leading cause of infertility. Ongoing monitoring for cardiometabolic risks is essential throughout life, and pregnancy demands particular vigilance, as PMOS elevates the chances of gestational diabetes, pre-eclampsia, low blood sugar episodes, and the need for neonatal intensive care admission. Miscarriage rates are also higher. Mental health support is increasingly recognized as part of comprehensive care, given the condition's documented associations with depression, anxiety, bipolar disorder, and reduced overall quality of life.